Deep cuts to HIV research could halt decades of progress, scientists say
The Trump administration this week decimated HIV prevention programs across government health agencies after terminating ...
Coffee-based approach yields promising results in ovarian cancer trial
University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...
PharmExec14h
Teva’s Novel Schizophrenia Drug Candidate Demonstrates High Patient, Provider Satisfaction in Phase III Trial Survey
Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall ...
Medical Dialogues12h
Pfizer Gets CDSCO Panel Nod To study Marstacimab
New Delhi: The pharmaceutical major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the ...
Fierce Biotech9h
Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers
Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year.  | Relay ...
PharmExec14h
Winrevair Found to Significantly Reduce the Risk of Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension
Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...
Are Psychedelics A Way To Fast-Track Healing Trauma? We Road-Tested Ketamine
Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried ...
Targeted Oncology8h
Addressing Treatment Gaps in High-Risk CML in Blast Phase
Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.
Brokerages Set Affimed (NASDAQ:AFMD) Price Target at $13.50
Affimed (NASDAQ:AFMD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. One equities ...
Breakthrough HIV trial in South Africa offers hope for drug-free remission — first of its kind in Africa
Professor Thumbi Ndung'u and his team at the Africa Health Research Institute are pioneering a study that explores innovative ...
CURE9h
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...
Galectin Therapeutics (NASDAQ:GALT) Given Neutral Rating at HC Wainwright
Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on ...